, Small Molecules and Biologics CDMO, Secures Equity Investment and Appoints new CEO
Summary
OSLO, NORWAY Curida Holding AS (Curida) has announced a significant growth investment from Signet Healthcare Partners (Signet), a New York-based healthcare private equity firm together with existing shareholders, Canica, Investinor, Klaveness Marine and Farvatn Private Equity. This investment will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position. We are excited by the opportunity to further accelerate growth and improve products for our pharma and biotech customers in their work to deliver medicines and therapeutics to benefit patients. Curida focuses on aseptic and non-aseptic liquid manufacturing and specializes in blow-fill-seal (BFS) and nasal spray technologies to serve the Small Molecules pharmaceutical and medical device market. Curidas customer base ranges from small to medium-sized pharmaceutical and biotech companies, delivering solutions in drug development and GMP manufacturing globally.